Sandu Pharma Q1 FY27: PAT flat at 23.32L, revenue dips, new auditor appointed

Revenue DeclineRelated Party TransactionsAuditor Mid Year ChangeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.7%1-day move

₹39.25

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——

Up moveDown movePending

AI summary

Sandu Pharma's board approved Q1 FY27 (ended June 2026) unaudited standalone results. Revenue from operations dipped to 1638.88L from 1669.90L YoY. Total income was 1640.62L vs 1671.67L. PAT nearly flat at 23.32L vs 23.23L, while PBT rose to 36.05L from 33.87L. EPS stood at 0.37 vs 0.23. Auditor Dileep and Prithvi issued an unmodified limited review report. Board also approved appointing M/s. Dave and Dave as new statutory auditor for a five-year first term and recommended material related party transactions with Sandu Brothers Pvt Ltd for member approval. 41st AGM set for 11 Sept 2026, record date 4 Sept for dividend.

Likely market impact

Marginal revenue dip with stable PAT is neutral to mildly negative. Watch the auditor change and material related party deal needing member approval at AGM.